Keyphrases
Clinical Significance
100%
Hypermethylation
100%
Gastric Cancer
100%
DNA Methylation (DNAm)
100%
High-resolution Arrays
100%
Plasma Samples
72%
Tissue Sampling
54%
FLI1
54%
Gastric Cancer Patients
36%
Liver Metastasis
27%
Lymph Node Metastasis
18%
5-year Survival
18%
Hypermethylated Genes
18%
ADAM19
18%
Tumor
9%
Patient Survival
9%
Tumor Recurrence
9%
Liver
9%
Aberrant DNA Methylation
9%
Methylation
9%
Hypermethylated
9%
Overall Survival
9%
Survival Analysis
9%
Disease-free Survival
9%
Gastric Carcinoma
9%
CpG Sites
9%
DNA Promoter
9%
Subgroup Analysis
9%
Non-tumor Tissue
9%
Validation Set
9%
DNA Methylation Analysis
9%
Independent Prognostic Factor
9%
Recurrence Pattern
9%
Advanced Gastric Cancer
9%
Stage III Gastric Cancer
9%
Superficial Type
9%
Para-aortic Lymph Node Metastasis
9%
Stage IV Gastric Cancer
9%
Gastric Cancer Recurrence
9%
Biochemistry, Genetics and Molecular Biology
DNA Methylation
100%
Blood Plasma
100%
FLI1
75%
Epstein Barr Virus
37%
Disease Free Survival
37%
Methylation
25%
Survival Rate
25%
Promoter Region
12%
Overall Survival
12%
Carcinogenesis
12%
CpG Site
12%
Pharmacology, Toxicology and Pharmaceutical Science
Abdominal Cancer
100%
Lymph Node Metastasis
23%
Disease Free Survival
23%
Liver Metastasis
23%
Biological Marker
15%
Survival Rate
15%
Carcinogenesis
7%
Neoplasm
7%
Overall Survival
7%
Tumor Recurrence
7%
Cancer Recurrence
7%